We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Codexis Achieves Development Milestone in Research Agreement with Schering-Plough

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Codexis Achieves Development Milestone in Research Agreement with Schering-Plough"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Codexis, Inc. has announced that it has achieved an important development milestone under a research agreement with Schering-Plough Corporation

The objective of the collaboration with Schering-Plough is to generate a biocatalytic process to produce a key intermediate for an undisclosed human therapeutics compound.

This program is based on Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.

"The agreement with Schering-Plough was announced in March, and Codexis has quickly met the initial development milestone," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.

"We are very pleased with this substantial progress in our collaboration and look forward to continuing to demonstrate the value of our technology to this important partner."

"An increasing number of worldwide pharmaceutical partners are recognizing the Codexis competitive advantage in developing rapid, efficient clinical-scale manufacturing production processes."